Evidence map›Paper›PMID 22732331›Full record

Trial reportClinical nephrology2012

Dissociation between progression of coronary artery calcification and endothelial function in hemodialysis patients: a prospective pilot study.

Roberto S Kalil, Michael Flanigan, William Stanford, William G Haynes

Open access · greenAbstract readComparative StudyRandomized Controlled Trial
PubMed Full text at PMC Publisher
In one paragraph

Trial report in Clinical nephrology, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers, 4 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
16citing papers in PubMed, 4 pooled it
1.1field-weighted citation impact, top 23% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

16 citing papers in PubMed, 4 syntheses or guidelines pooled it, 31 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Pooled it
  5. Optimal Phosphate Control Related to Coronary Artery Calcification in Dialysis Patients.Journal of the American Society of Nephrology : JASN · 2021
    Trial
  6. Trial
  7. Trial
  8. Review
  9. Article
  10. Article
  11. Article
  12. Article
  13. Article
  14. Article
  15. Review
  16. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors at 2 institutions in 1 country.

Roberto S KalilDepartment of Internal Medicine, Roy J. and Lucille Carver College of Medicine, University of Iowa, Iowa City, IA 52240, USA. Roberto-kalil@uiowa.edu
Michael Flanigan
William Stanford
William G Haynes
University of Iowa · USMarshfield Clinic · US

Funding

HYPOXIC MODULATION OF ION CHANNELS IN PULMONARY ARTERYF32HL008410 · NHLBI · UNIVERSITY OF NEVADA RENO · PI POST, JOSEPH M · 1990 to 1992
–
NHLBI NIH HHS 5K23 HL08410-02NHLBI NIH HHS P50 HL14388
6 · The paper itself

Abstract

unlabelledChronic kidney disease profoundly disturbs calcium-phosphate metabolism and predisposes to premature atherosclerosis. Both coronary artery calcification (CAC) and endothelial dysfunction are common in hemodialysis (HD) patients. We hypothesized that a calcium-free phosphate binder would improve endothelial function and delay progression of vascular calcification in HD patients.

methodsThis was a randomized parallel-group trial in HD patients comparing lanthanum carbonate (LC) with a non-LC phosphorus binders control group (non-LC) at a 1 : 1 randomization. CAC was obtained at baseline, 6, and 12 months, and endothelial function (brachial artery flow-mediated dilation - FMD) at baseline and 6 months.

results13 patients were randomized (LC n = 7 and non-LC n = 6). CAC scores (Log ± SE) at baseline were 7.21 ± 0.62 (LC) and 6.07 ± 0.73 (control). CAC increased in the non-LC group (33 ± 17% and 77 ± 22% at 6 and 12 months), but tended to decrease in the LC group (-10 ± 11% and -2 ± 11% at 6 and 12 months). There was statistically less progression in CAC in the LC group compared to control at 6 (p = 0.002) and 12 months (p = 0.003). There was no difference between groups in FMD (p = 0.7). Markers of inflammation did not change significantly.

conclusionA slower rate of progression of CAC occurred in the LC group, independent of changes in FMD. This is the first study showing dissociation between progression of CAC and FMD in HD patients. Larger studies are warranted to elucidate the impact of different phosphate sequestration therapies on atherosclerosis in HD patients.

Indexed as

Renal DialysisAgedBiomarkersBrachial ArteryCalciumChelating AgentsChronic DiseaseCoronary Artery DiseaseDisease ProgressionEndothelium, VascularHumansIowaKidney DiseasesLanthanumMiddle AgedPhosphorusBiomarkersCalciumChelating AgentsLanthanumlanthanum carbonatePhosphorusPolyaminesSevelamer

Identifiers

PMID22732331
PMCPMC4407338
OpenAlexW2090323715

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.